Ride the Reversal in Express Scripts

September's profit taking in ESRX has finally waned


Express Scripts (ESRX) — Following its merger with Medco Health Solutions in 2012, Express Scripts is the largest player in the pharmacy benefits management industry, managing more than 1 billion prescriptions annually for tens of millions of patients.

Analysts expect ESRX to grow at much higher-than-average industry rates thanks to cost synergies from Medco, expansion of mail-order generics, and the phasing-in of health insurance coverage under the Affordable Care Act. Express Scripts earned $1.79 in 2012; the consensus estimate for 2013 is $4.31 and analysts look for $4.94 in 2014. Price targets range from $73.50 to $80.

Last July, after it favorably ended a dispute with Walgreen (WAG), we placed ESRX on the buy list at $59 with a trading target of $66, which it achieved on Oct. 5. The stock fell from favor in late 2012 but held on its bullish support line in November and advanced to a high of over $67 in July of this year. This September profit taking dropped ESRX close to its bullish support line and 200-day moving average, where it reversed on Tuesday following three days of high-volume buying.

Buy Express Scripts at under $64 with a trading objective of $73. Investors might want to hold ESRX as a long-term holding with expectations of high growth in the healthcare sector.

ESRXbuy 300x197 Ride the Reversal in Express Scripts
Click to Enlarge

chart key Ride the Reversal in Express Scripts

Article printed from InvestorPlace Media, http://investorplace.com/2013/09/trade-of-the-day-express-scripts-esrx/.

©2015 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.